Today: 27 November 2025
Subscribe
Browse Tag

pharmaceutical industry

Eli Lilly (LLY) Stock on November 26, 2025: Trillion‑Dollar Milestone, Pricing Shake‑Up and Stock‑Split Buzz

Eli Lilly (LLY) Stock on November 26, 2025: Trillion‑Dollar Milestone, Pricing Shake‑Up and Stock‑Split Buzz

Eli Lilly and Company (NYSE: LLY) is having another headline‑heavy session on Wednesday, November 26, 2025, as investors digest its new status as the first trillion‑dollar healthcare company, fresh moves on obesity‑drug pricing, and growing chatter about a potential stock
26 November 2025
 ·  ·  ·  ·  · 
Big Pharma’s Billion-Dollar Bet: Inside Eli Lilly’s $5B Virginia Factory and America’s New Drug Manufacturing Boom

Eli Lilly (LLY) Stock Today, November 22, 2025: Trillion‑Dollar Milestone, New Board Member and Fresh Access Deals Fuel Momentum

Eli Lilly (NYSE: LLY) heads into the weekend of November 22, 2025, sitting near record highs and fresh off becoming the first drugmaker ever to join the $1 trillion market‑cap club. A powerful combination of blockbuster obesity drugs, new access deals
22 November 2025
 ·  ·  ·  ·  · 
Johnson & Johnson’s $3.05 Billion Halda Therapeutics Deal Signals New Oncology Push After Stelara Patent Cliff

Johnson & Johnson’s $3.05 Billion Halda Therapeutics Deal Signals New Oncology Push After Stelara Patent Cliff

Johnson & Johnson has struck a $3.05 billion cash deal to acquire Halda Therapeutics, a privately held cancer-drug developer based in New Haven, Connecticut, in one of 2025’s biggest oncology takeovers so far. Reuters+1 The move deepens J&J’s bet on
17 November 2025
 ·  ·  ·  ·  ·  ·  ·  · 
Merck to Buy Cidara Therapeutics for $9.2 Billion in Bold Bet on Long‑Acting Flu Prevention

Merck to Buy Cidara Therapeutics for $9.2 Billion in Bold Bet on Long‑Acting Flu Prevention

Merck & Co. (NYSE: MRK) has agreed to acquire Cidara Therapeutics (Nasdaq: CDTX) in a deal valued at about $9.2 billion, a blockbuster move that gives the pharma giant a late‑stage, long‑acting influenza prevention drug as it prepares for life
14 November 2025
 ·  ·  ·  ·  ·  · 
Pfizer Stock Surges 15% on Trump’s Pricing Pact & $7.3B Obesity Deal – Can the Rally Last?

Pfizer Stock (PFE) Before the Bell on November 14, 2025: Metsera Deal Closes, BioNTech Stake Cut and Guidance Raised

As Wall Street heads into Friday’s session, Pfizer stock is trading slightly lower in premarket action while investors digest a trio of big developments: the completed acquisition of obesity‑drug developer Metsera, a sharp reduction in Pfizer’s stake in BioNTech, and
14 November 2025
 ·  ·  ·  ·  ·  · 
InflaRx (IFRX) pops on positive INF904 Phase 2a results in HS & CSU; Q3 filing shows €44.4M liquidity and runway into 2027 — Nov 10, 2025

InflaRx (IFRX) pops on positive INF904 Phase 2a results in HS & CSU; Q3 filing shows €44.4M liquidity and runway into 2027 — Nov 10, 2025

InflaRx N.V. (NASDAQ: IFRX) surged into today’s session after unveiling topline Phase 2a data for its oral C5aR inhibitor INF904 in hidradenitis suppurativa (HS) and chronic spontaneous urticaria (CSU), alongside filing its third‑quarter Form 6‑K showing €44.4 million of available
10 November 2025
 ·  ·  ·  ·  · 
Pfizer (PFE) Clinches $10B Metsera Deal, Beating Novo Nordisk — What the Winning Bid Means for the Obesity-Drug Race (Nov. 8, 2025)

Pfizer (PFE) Clinches $10B Metsera Deal, Beating Novo Nordisk — What the Winning Bid Means for the Obesity-Drug Race (Nov. 8, 2025)

Pfizer Inc. (NYSE: PFE) has secured a definitive agreement to acquire weight‑loss biotech Metsera in a transaction valued at up to $10 billion, ending a high‑stakes bidding war with Novo Nordisk and positioning Pfizer squarely back in the fast‑growing obesity
8 November 2025
 ·  ·  ·  ·  ·  · 
1 2
Go toTop